Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly

In the phase II IM103‐100 study, kidney transplant recipients were first randomized to belatacept more‐intensive‐based (n = 74), belatacept less‐intensive‐based (n = 71), or cyclosporine‐based (n = 73) immunosuppression. At 3‐6 months posttransplant, belatacept‐treated patients were re‐randomized to...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincenti, F., Blancho, G., Durrbach, A., Grannas, G., Grinyó, J., Meier‐Kriesche, H.‐U., Polinsky, M., Yang, L., Larsen, C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724691/
https://www.ncbi.nlm.nih.gov/pubmed/28758341
http://dx.doi.org/10.1111/ajt.14452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724691/
https://www.ncbi.nlm.nih.gov/pubmed/28758341
http://dx.doi.org/10.1111/ajt.14452

Ejemplares similares